CPT code 86769 identifies a multiple-step immunoassay used to detect serum antibodies to SARS–CoV–2, the virus responsible for COVID‑19. As a serologic test, it plays a role in determining prior infection or immune response and is relevant for clinical interpretation, public health surveillance, and laboratory billing workflows nationwide. The code is used across hospital and independent clinical laboratories and factors into national laboratory testing patterns and payer coverage policies.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context for serologic testing, the typical sites of service where the assay is performed, and the implications for billing and claims processing. The publication summarizes benchmark metrics, common modifier usage patterns, and payer coverage considerations where available. It also outlines regulatory and policy developments that affect lab-based SARS–CoV–2 antibody testing, and highlights operational considerations for laboratories submitting claims.

This summary is intended for a national audience of health policy analysts, billing professionals, and laboratory administrators seeking a clear overview of CPT code 86769, its clinical purpose, and the payer landscape relevant to serologic SARS–CoV–2 testing. Data not available in the input are noted where applicable.